Literature DB >> 16861890

L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes.

Damon Banks1, Min Wu, Leigh Ann Higa, Nadia Gavrilova, Junmin Quan, Tao Ye, Ryuji Kobayashi, Hong Sun, Hui Zhang.   

Abstract

The CUL4-ROC1 E3 ligase complex regulates genome stability, replication and cell cycle progression. A novel WD40 domain-containing protein, L2DTL/CDT2 and PCNA were identified as proteins associated with CUL4/DDB1 complexes. Inactivation of CUL4A, L2DTL, PCNA, DDB1 or ROC1 induced p53 stabilization and growth arrest. L2DTL, PCNA and DDB1/CUL4A complexes were found to physically interact with p53 tumor suppressor and its regulator MDM2/HDM2. The isolated CUL4A complexes display potent and robust polyubiquitination activity towards p53 and this activity is dependent on L2DTL, PCNA, DDB1, ROC1 and MDM2/HDM2. We also found that the interaction between p53 and CUL4 complex is regulated by DNA damage. Our data further showed that MDM2/HDM2 is rapidly proteolyzed in response to UV irradiation and this process is regulated by CUL4/DDB1 and PCNA. Our studies demonstrate that PCNA, L2DTL and the DDB1-CUL4A complex play critical and differential roles in regulating the protein stability of p53 and MDM2/HDM2 in unstressed and stressed cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861890     DOI: 10.4161/cc.5.15.3150

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  64 in total

1.  Prognostic significance of miR-215 in colon cancer.

Authors:  Mihriban Karaayvaz; Timothy Pal; Bo Song; Cecilia Zhang; Penelope Georgakopoulos; Saira Mehmood; Stephanie Burke; Kenneth Shroyer; Jingfang Ju
Journal:  Clin Colorectal Cancer       Date:  2011-07-12       Impact factor: 4.481

Review 2.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 3.  Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation.

Authors:  Jason L Dehart; Vicente Planelles
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

4.  E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation.

Authors:  Anand Thirunavukarasou; Prachi Singh; Gokulapriya Govindarajalu; Venkateshwarlu Bandi; Sudhakar Baluchamy
Journal:  Mol Cell Biochem       Date:  2014-01-23       Impact factor: 3.396

5.  The E3 ubiquitin ligase Cullin 4A regulates meiotic progression in mouse spermatogenesis.

Authors:  Yan Yin; Congxing Lin; Sung Tae Kim; Ignasi Roig; Hong Chen; Liren Liu; George Michael Veith; Ramon U Jin; Scott Keeney; Maria Jasin; Kelle Moley; Pengbo Zhou; Liang Ma
Journal:  Dev Biol       Date:  2011-05-23       Impact factor: 3.582

6.  Antiproliferative and apoptotic-inducing potential of ellagic acid against 1,2-dimethyl hydrazine-induced colon tumorigenesis in Wistar rats.

Authors:  Syed Umesalma; Ponnuraj Nagendraprabhu; Ganapasam Sudhandiran
Journal:  Mol Cell Biochem       Date:  2013-11-27       Impact factor: 3.396

7.  Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.

Authors:  Nektarios Barabutis; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

8.  RBX1/ROC1-SCF E3 ubiquitin ligase is required for mouse embryogenesis and cancer cell survival.

Authors:  Lijun Jia; Yi Sun
Journal:  Cell Div       Date:  2009-08-06       Impact factor: 5.130

9.  Proliferation defects and genome instability in cells lacking Cul4A.

Authors:  D Kopanja; T Stoyanova; M N Okur; E Huang; S Bagchi; P Raychaudhuri
Journal:  Oncogene       Date:  2009-05-11       Impact factor: 9.867

10.  Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer.

Authors:  J Li; E K O Ng; Y P Ng; C Y P Wong; J Yu; H Jin; V Y Y Cheng; M Y Y Go; P K F Cheung; M P A Ebert; J Tong; K F To; F K L Chan; J J Y Sung; N Y Ip; W K Leung
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.